Use the link above to search for these suggested keywords:
– Gastrointestinal Cancer
– Bladder Cancer
– Colorectal Cancer
– Liver Cancer
– Pancreatic Cancer
– Rectal Cancer
– Renal/Kidney Cancer
More clinical trials are available on NIH’s national clinical trial database.
Appointments:
(202) 444-2223
Office: 202-444-0275
Fax: (202) 444-1229
rueschcenter@ georgetown.edu
John Marshall, MD
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers; Physician Executive Director, MedStar Washington DC Integrated Hematology Oncology Division; Chief, Division of Hematology and Oncology, MedStar Georgetown University Hospital; Professor of Medicine and Oncology, Georgetown University School of Medicine; Chief Medical Officer, Georgetown Lombardi, MedStar Georgetown Cancer Institute
You will be redirected to our clinical partner, MedStar Health.
Gastrointestinal (GI) cancers remain among the most fatal cancers. Advances in treatment have lagged well behind other disease priorities such as breast cancer because of a smaller pool of research funding and fewer survivors to carry the torch of advocacy.
The Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center and MedStar Georgetown University Hospital focuses on national efforts on curing this deadly set of diseases. Combining expertise in molecular medicine, translational research, and a patient-centered philosophy, the Ruesch Center realizes the dream of individualized curative therapies through research, care, and advocacy.
From the National Cancer Institute at the National Institutes of Health, find current information and resources on gastrointestinal cancers, incidence and survival statistics, treatment options, causes and prevention, coping strategies, clinical trials and research.
Learn more about treatment for the following gastrointestinal cancers available through our clinical partner, MedStar Health:
Gastrointestinal cancers include: Anal Cancer, Colorectal (Colon) Cancer, Esophageal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumors, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer.
Dramatic improvements in molecular biology have led to a better understanding of what makes cancers “tick.” New anti-cancer agents are being developed at an unprecedented pace. New technologies allow us to measure the many variables quickly and accurately. Improvements in bioinformatics allow us to analyze the resulting data sets. These advances form the foundation of personalized medicine, the only way forward in the quest to cure cancer.
Georgetown Lombardi’s world-renowned research faculty are discovering cancer risk factors, designing effective prevention strategies, and learning how to detect cancers earlier. They are developing and testing the cancer treatments of tomorrow — targeted therapies that will improve both survival and quality of life. They are making progress toward the ultimate goal: to eradicate cancer.
Types of Bacteria Vary Widely in Tumors of People with Early vs. Late-Onset Colorectal Cancer
May 25th, 2023
Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center studied the microbiome of people with colorectal cancer and found the makeup of the bacteria, fungi and viruses in a person’s tumor varied significantly depending on whether they were diagnosed with early onset disease (age 45 or younger) or late-onset disease (age 65 or older). …
Georgetown Lombardi Oncologists Encourage Patients to Keep Up with Cancer Screenings
November 20th, 2020
…
